Serum concentrations of erlotinib at a dose of 25 mg daily

Por Costa, Daniel B., Yeo, Wee-Lee, Hamada, Akinobu, Kobayashi, Susumu
Publicado em 2010

Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in NSCLC

Por Pal, Sumanta K., Reckamp, Karen L.
Publicado em 2010

From Mice to Men and back – an assessment of preclinical model systems for the study of lung cancers

Por Gazdar, Adi F., Hirsch, Fred R., Minna, John D.
Publicado no J Thorac Oncol (2015)

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma

Por Chaft, Jamie E., Rekhtman, Natasha, Ladanyi, Marc, Riely, Gregory J.
Publicado em 2012

Targeting MEK for the Treatment of Non Small-Cell Lung Cancer

Por Goldman, Jonathan W., Garon, Edward B.
Publicado em 2012

Oncogenic Fusions Involving Exon 19 of ALK

Por Le, Anh T., Varella-Garcia, Marileila, Doebele, Robert C.
Publicado em 2012

Answer to the Letter to the Editor: No increased risk for mesothelioma in relation to natural-occurring asbestos in Southern Nevada

Por Baumann, Francine, Buck, Brenda J., Metcalf, Rodney V., McLaurin, Brett T., Merkler, Doug, Carbone, Michele
Publicado no J Thorac Oncol (2015)

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers

Por Klempner, Samuel J., Cohen, David W., Costa, Daniel Botelho
Publicado no J Thorac Oncol (2011)

Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition

Por Levin, Pavel A., Mayer, Melissa, Hoskin, Sharon, Sailors, Joseph, Oliver, Dwight H., Gerber, David E.
Publicado no J Thorac Oncol (2015)

Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement

Por Khozin, Sean, Roth, Mark J., Rajan, Arun, Smith, Karen, Thomas, Anish, Berman, Arlene, Giaccone, Giuseppe
Publicado em 2012

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small cell lung cancer

Por Rudin, Charles M., Hong, Kelvin, Streit, Michael
Publicado em 2013

Erlotinib response in a NSCLC patient with a novel compound G719D+L861R mutation in EGFR

Por Berge, Eamon M, Aisner, Dara, Doebele, Robert C
Publicado em 2013

Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer

Por Prudkin, Ludmila, Tang, Ximing, Wistuba, Ignacio I.
Publicado no J Thorac Oncol (2009)

Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib

Por Hellmann, Matthew D., Reva, Boris, Yu, Helena, Rusch, Valerie W, Rizvi, Naiyer A, Kris, Mark G, Arcila, Maria E
Publicado no J Thorac Oncol (2014)

Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma

Por Shea, Meghan, Huberman, Mark S., Costa, Daniel B.
Publicado no J Thorac Oncol (2016)

Cisplatin versus carboplatin based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data

Por Santana-Davila, Rafael, Szabo, Aniko, Arce-Lara, Carlos, Williams, Christina D., Kelley, Michael J., Whittle, Jeff
Publicado no J Thorac Oncol (2014)

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer

Por Ackerman, Allison, Goldstein, Michael A., Kobayashi, Susumu, Costa, Daniel B.
Publicado em 2012

Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles

Por Rekhtman, Natasha, Borsu, Laetitia, Reva, Boris, Arcila, Maria, Riely, Gregory J., Ladanyi, Marc, Drilon, Alexander
Publicado em 2014

KRAS mutation analysis helps differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma

Por Ortiz, Taylor M., Cohen, David W., Kent, Michael S., Jänne, Pasi A., Costa, Daniel B.
Publicado em 2011

A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision withTreatment Including Pemetrexed and Bevacizumab

Por Riess, Jonathan W, Nagpal, Seema, Das, Millie, Neal, Joel W., Kim, Jonathan W., Wakelee, Heather A.
Publicado em 2013